Smith Jeffrey T. L. - 03 Jan 2024 Form 3 Insider Report for Zymeworks Inc. (ZYME)

Role
EVP & Chief Medical Officer
Signature
/s/ Daniel Dex, Attorney-in-Fact
Issuer symbol
ZYME
Transactions as of
03 Jan 2024
Net transactions value
$0
Form type
3
Filing time
05 Jan 2024, 18:00:08 UTC
Next filing
08 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ZYME No securities are beneficially owned 0 03 Jan 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ZYME Stock Option (Right to Buy) 03 Jan 2024 Common Stock 188,000 $8.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Stock options vest as follows: (i) 25% of underlying shares of common stock on January 5, 2024 (the first anniversary of grant date) and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of each month following first anniversary of grant date.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney